Navigation Links
The 2200

ProductsThe 2200
Company Advanced Meditech International, Inc.
Item The 2200
Features 
Description The 2200 is ideal for applications such as vasectomy that require accurate application of heat.

The autoclavable handpiece with six-foot cord accepts an assortment of reusable thermal cautery electrodes, allowing the physician to have the flexibility to perform a wide variety of procedures.

The 2200 includes the unit, 1 handpiece, and the general purpose A,C, & E electrodes.

Info Advanced Meditech International, Inc.
Customer Service: (800) 635-2452
Web site: http://www.ameditech.com/

Related medicine products :

1. Kimura Platinum Spatula
2. Midas Rex Legend Platinum
3. Midas Rex Legend Platinum Drill System
4. Clinac 21EX Platinum
5. Clinac 23EX Platinum
6. Platinum Plus
7. Contour Design Eyelid Implants (Platinum)
8. E-Z Frame Platinum
9. Contour Gold/Platinum Eyelid Implants
10. Invacare Platinum 10 Oxygen Concentrator with Sens O2
11. Invacare Platinum 10 Oxygen Concentrator
TAG: The
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
Medicine Products:
(Date:11/21/2008)...la., Nov. 21 Unilens Vis...Exchange: UVI), which develops, licenses,manufac...enses, today reported,its operating results for t.... , Net sales, excluding royalty income, in...r, compared with $1,673,361 in the previous year f...
(Date:11/21/2008)...ll easier to take, has fewer side effects than ch... 21 (HealthDay News) -- The cancer-fighting pill I...ne treatment for lung cancer, researchers report. ...yond eight months, Iressa (gefitinib) causes fewer...or patients who did not do well on their first rou...
(Date:11/21/2008)..., Nov. 21 Keryx Biopharm... that on November 17, 2008, it received notice fro...the Company is no longer in compliance with Market...to have a minimum of $2,500,000 in stockholders, e...ities, or $500,000 of net income from continuing o...
(Date:11/21/2008)...hina, Nov. 21 Huifeng Bi...oard: HFGB), a leading developer and producer,of ...r use in pharmaceutical,nutraceutical and food p...,earnings for the three and nine month periods en...o announce that in the third quarter of 2008, Huif...
Breaking Medicine News(10 mins):Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 2Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 3Health News:Unilens Vision Reports Record First Quarter Revenue, Earnings and Royalty Income 4Health News:Iressa as Good as Chemotherapy for Lung Cancer 2Health News:Iressa as Good as Chemotherapy for Lung Cancer 3Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 2Health News:Keryx Biopharmaceuticals Receives Nasdaq Notification 3Health News:Huifeng Bio-Pharmaceutical (HFGB) Reports Record Sales and Net Income 2
...Sudan are at a higher risk of developing HIV/AIDS,...npower, Alison Manani Magaya has warned. Khartoum ...t a graduation ceremony for an HIV/AIDS training p...of refugees from other countries having a high pre...
...diction and Mental Health has said, there appears ...onsumption of alcohol and the increasing rate of s...t even a one-litre increase in the consumption of ...e in the suicide rate. "Alcohol tends to have di...
...w weeks, many college students left the comforts o...ers. Getting away from mom and dad may be great, b...he foot fungus and wart-causing virus that can be ...showers are one of the easier places to contract f...
...ed to certain harmful chemicals before they are ev...e need for pregnant women to be careful about thei...nosa at the University of Granada, Spain, tested b...of pregnant women and found up to 15 different typ...
Other Medicine News:Health News:Tips for Avoiding Foot Fungus in Communal Bathrooms 2Health News:Babies in Womb Exposed to Harmful Chemicals 2
(Date:11/21/2008)...D OAKS, Calif., Nov. 21 ...European Committee for Medicinal,Products for Hum...ending,marketing authorisation for Nplate(TM) (ro...recommends Nplate for adult chronic immune (idiopa...ed patients who are refractory to,other treatment...
(Date:11/21/2008)...EAD, England, November 21 /PRNewswire-FirstCall/ -...uropean Committee for Medicinal Products for Human...dation for the approval of Enbrel(R),(etanercept)... and,adolescents with severe plaque psoriasis. If...he Committee,s recommendation, Enbrel will become ...
(Date:11/21/2008)..., N.J., Nov. 21 Ikaria Holdings, I... Company of the Year by the New Jersey Technology ...tion that provides business support, networking op...gy companies and their leaders. Ikaria earned the ...p and unique product/service provision. , , ...
(Date:11/20/2008)...INO, Calif., Nov. 20 Epeius Biotec...II and II studies of Rexin-G in,chemotherapy-resi...oma, as,presented by Dr. Sant P. Chawla, principa...held in London UK on November 13-15, 2008. Patient...r a period up to 9 months. Analysis of,safety and...
Breaking Medicine Technology:Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 2Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 3Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 4Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 5Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 6Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 7Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union 8CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Soft Tissue Sarcoma and Osteosarcoma: Phase I/II & Confirmatory Phase II Studies 2United Therapeutics Reports Third Quarter 2007 Financial Results 1642 1United Therapeutics Reports Third Quarter 2007 Financial Results 1642 2United Therapeutics Reports Third Quarter 2007 Financial Results 1642 3United Therapeutics Reports Third Quarter 2007 Financial Results 1642 4United Therapeutics Reports Third Quarter 2007 Financial Results 1642 5United Therapeutics Reports Third Quarter 2007 Financial Results 1642 6United Therapeutics Reports Third Quarter 2007 Financial Results 1642 7United Therapeutics Reports Third Quarter 2007 Financial Results 1642 8United Therapeutics Reports Third Quarter 2007 Financial Results 1642 9Neurocrine Biosciences and Dainippon Sumitomo Pharma 28DSP 29 Announce Agreement to Develop and Commercialize Indiplon in Japan 1640 1Neurocrine Biosciences and Dainippon Sumitomo Pharma 28DSP 29 Announce Agreement to Develop and Commercialize Indiplon in Japan 1640 2Neurocrine Biosciences and Dainippon Sumitomo Pharma 28DSP 29 Announce Agreement to Develop and Commercialize Indiplon in Japan 1640 3Biopure Announces Pricing of Equity Offering 1638 1Biopure Announces Pricing of Equity Offering 1638 2Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 1Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 2Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 3Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 4Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 5Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 6Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 7Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 8Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 9Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 10Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 11Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 12Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 13Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 14Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 15Millennium Reports Outstanding Third Quarter Results Driven by VELCADE 28R 29 28Bortezomib 29 for Injection Sales 1636 16
...on-free survival in,the SPARC Phase 3 trial consis... disease progression for patients receiving,satrap...,geographies, as well as presence or absence of pa... -- Pharmion,Corporation and GPC Biotech AG today ... the double-blind, randomized satraplatin Phase,3 ...
...TC 40983 (EPOC),Intergroup Study Results, CHICAGO,...f the,randomized phase III EORTC 40983 Intergroup ...me that peri-operative (pre and post,surgery) FOLF...ation with a standard chemotherapy regimen for col...ven to patients with,resectable liver metastases f...
Other Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 2The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 3The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 4The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 5The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 6The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 7The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 8The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved,Progression Free Survival When Given Before and After Surgery in,Patients With Resectable Liver Metastases From Colorectal Cancer 9